Momentum Multi-Asset Value Trust is a multi-asset trust offering global exposure to a diversified range of asset classes and sources of return, across traditional assets such as UK and overseas equity, as well as specialist areas, including infrastructure, property, private equity and alternative income.
The trust aims to return consumer-price inflation plus 6% per year over a typical investment cycle with a mix of income and capital growth. It applies a refined value, contrarian approach to stock selection, whereby each portfolio investment presents greater upside than the market anticipates.
Syncona: spotting winners in life sciences
Syncona (LSE: SYNC) is a private-equity trust focused on life-sciences firms, which funds initial ideas with venture capital, funding growth through the clinical-trials phase until their products are released. The team has a good record of success, with three firms maturing and sold in recent years. Blue Earth Diagnostics, Nightstar Therapeutics and Gyroscope were sold for a return of three times (with the potential of up to 5.1 times), 4.5 times and ten times the initial investment, respectively.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The portfolio consists of eleven companies diversified across a range of therapeutic areas, all at different stages of development. As Syncona-funded products move through clinical trials there will be some winners and some losers, but we feel the management team has demonstrated its ability to develop successful businesses with asymmetric return profiles. Syncona has numerous products with important milestones in clinical trials this year and the shares have sold off from a high of 302p in 2018.
Ediston Property Investment: retail parks are resilient
Ediston Property Investment (LSE: EPIC) owns a number of retail parks and is still recovering from the Covid-19 crisis. Vacancy rates increased with retailers becoming bankrupt and short-term adjustments to rental contracts for firms affected by the pandemic. All of this was against the backdrop of online retail gaining market share. Net asset value (NAV) has dropped significantly from reduced property valuations and lower income. Based on a share price of 75.4p, it is trading on a discount to NAV of 16.4%.
However, out-of-town retail parks are displaying resilience. Hybrid working is resulting in a shift from city-centre stores to retail parks. The growth in online transactions is being supported by the ability to return stock to shops or take up click-and-collect purchases. All these factors point to the shares offering significant value.
Vistry: a fast-growing builder at a good price
UK property prices have reached a new peak and demand remains strong. There is a shortage of housing and the building of new houses is still below government targets. Vistry (LSE: VTY) is a UK housebuilder trading on a very attractive valuation that recently announced record sales. Dividends resumed last year and are at an all-time high, offering a well-covered 6.2% yield.
As a result of the Grenfell disaster, there is still some uncertainty over what the cost to the industry will be as the government seeks to remove all unsafe cladding, but Vistry is confident that it is well provisioned. The share price implies a 15%-20% discount to book value and we believe the company is capable of generating a mid-teens return on equity.
-
Europe prepares to stand alone as Trump turns on UkraineSupport for old military alliances is wavering in the US under Donald Trump. Europe’s leaders are rushing to fill the void. Simon Wilson reports
-
8 of the best houses for sale with annexesThe best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
-
Should investors stay bullish and buy UK and US stocks?Opinion Ignore the Eeyores, says Max King. The outlook for stocks in both Britain and America remains auspicious
